Authors: Cokgor, I Akabani, G Kuan, CT Friedman, HS Friedman, AH Coleman, RE McLendon, RE Bigner, SH Zhao, XG Garcia-Turner, AM Pegram, CN Wikstrand, CJ Shafman, TD Herndon, JE Provenzale, JM Zalutsky, MR Bigner, DD

Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872

Authors: Akabani, G Cokgor, I Coleman, RE Trotter, DG Wong, TZ Friedman, HS Friedman, AH Garcia-Turner, A Herndon, JE DeLong, D McLendon, RE Zhao, XG Pegram, CN Provenzale, JM Bigner, DD Zalutsky, MR

Citation: G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958

Authors: Kuan, CT Reist, CJ Foulon, CF Lorimer, IAJ Archer, G Pegram, CN Pastan, I Zalutsky, MR Bigner, DD

Citation: Ct. Kuan et al., I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts, CLIN CANC R, 5(6), 1999, pp. 1539-1549